The Evolving Treatment Landscape of Prostate Cancer
Daniel J. George, MD, says that clinicians who treat prostate cancer have devoted the past 70 years to hormone therapy and androgen deprivation therapy, particularly for patients with metastatic disease. However, the emergence of agents like docetaxel, abiraterone acetate, and androgen receptor antagonists, like apalutamide and enzalutamide, have changed the landscape.<br />
Daniel J. George, MD, medical oncologist, Duke Cancer Institute, says that clinicians who treat prostate cancer have devoted the past 70 years to hormone therapy and androgen deprivation therapy, particularly for patients with metastatic disease. However, the emergence of agents like docetaxel, abiraterone acetate (Zytiga), and androgen receptor (AR) antagonists, like apalutamide (Erleada) and enzalutamide (Xtandi), have changed the landscape.
Now that clinical studies have shown how all of these agents can benefit patients with prostate cancer, oncologists will have the opportunity to use some agents earlier and combinations with novel agents to increase benefit in the post-AR and post-chemotherapy settings. The number of possibilities is making room for more clinical trials that will help to prolong life in patients with prostate cancer.
The most exciting thing about the evolving landscape is that some of these agents will move on into the curative setting, says George.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
